(Q36734955)

16 August 2017

1 reference

title

Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases (English)

1 reference

16 August 2017

0 references

0 references

0 references

chronic liver disease

0 references

Sophie Lotersztajn

0 references

author name string

Ariane Mallat

series ordinal

1 reference

16 August 2017

Fatima Teixeira-Clerc

series ordinal

1 reference

16 August 2017

Vanessa Deveaux

series ordinal

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Therapeutic Targets

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

403-409

1 reference

Hepatic fibrosis: molecular mechanisms and drug targets

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Identification and functional characterization of brainstem cannabinoid CB2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

The endocannabinoid system as an emerging target of pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

The endocannabinoid system as a target for therapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

The endocannabinoid system and its therapeutic exploitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Identification of a high-affinity binding site involved in the transport of endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

CB1 cannabinoid receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Cannabinoids: potential anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Cannabinoid-based drugs as anti-inflammatory therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Current knowledge on the antagonists and inverse agonists of cannabinoid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Peripheral cannabinoid receptor, CB2, regulates bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Modulation of anxiety through blockade of anandamide hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Antifibrogenic role of the cannabinoid receptor CB2 in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

Anandamide induces necrosis in primary hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.3.403

10.1517/14728222.11.3.403

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference